{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-067387","form_type":"8-K","ticker":"COCH","cik":"0001840877","company_name":"Envoy Medical, Inc.","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.839723+00:00","generated_at":"2026-05-31T10:08:38.553532+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Envoy Medical Q2 revenue $68k, cash $1.7M; Acclaim CI pivotal trial goal by end-2024","bullets":["Revenue $68k (Q2 2024) vs $63k prior year; revenue from two Esteem units offset by battery sales decline.","R&D expenses rose $438k to $2.6M due to increased headcount for Acclaim CI pivotal study preparation.","Three EFS participants completed 18-month follow-up; all show CIQOL improvement, no SADEs/UADEs reported.","System noise mitigations implemented; two participants used hearing aid with Acclaim for better SNR.","Company maintains goal to submit IDE in coming months and start pivotal trial by year-end 2024; commercialization targeted by end-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-067387","json":"https://secwatch.observer/filing/0001213900-24-067387.json","markdown":"https://secwatch.observer/filing/0001213900-24-067387.md","text":"https://secwatch.observer/filing/0001213900-24-067387.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840877/000121390024067387/0001213900-24-067387-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840877/000121390024067387/ea0211068-8k_envoy.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:08:38.553532+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}